Page 1

Interim report 1 January - 30 September 2021 Q3 Intense launch preparations Third quarter : 1 July - 30 September 2021 Net sales amounted to SEK 1.1 million ( 0.0 ) . The operating result totalled SEK -50.0 million ( -50.0 ) . The result for the period amounted to SEK -49.1 million ( -48.7 ) . Earnings per share before and after dilution amounted to SEK -1.68 ( -1.80 ) . Cash flow from operating activities totalled SEK -63.0 million ( -46.7 ) . ● ● ● ● Period : 1 January - 30 September 2021 Net sales amounted to SEK 5.4 million ( 0.2 ) . The operating result totalled SEK -181.9 million ( -164.5 ) . The result for the period amounted to SEK -180.3 million ( -162.1 ) . Earnings per share before and after dilution amounted to SEK -6.46 ( -6.55 ) . Cash flow from operating activities totalled SEK -164.2 million ( -160.6 ) . As of 30 September 2021 , the Company had access to cash and cash equivalents of SEK 21.6 million ( 10.1 ) , short - term investments including short - term components of other securities held as non - current assets of SEK 207.5 million ( 296.7 ) and long - term listed corporate bonds of SEK 215.4 million ( 24.4 ) , totalling SEK 444.5 million ( 331.3 ) in available funds . ● • Significant events in the third quarter of 2021 ● ● No significant events took place during the quarter . after the end of the period Q - linea's partner Thermo Fisher Scientific announced the launch of ASTar for the European market . The Company signed the first commercial evaluation contract for ASTar with a Swedish regional hospital . The Company has commenced the reproducibility phase of the clinical study for ASTar market approval in the US . • Q - LINEA Q - LINEA | INTERIM REPORT | Q3 2021 1